Research Use Only: This product is supplied for laboratory research and in-vitro studies. Not for human or veterinary administration.

Identity Verified: LC-MS
(0 Reviews)

T -GLP-1 (15mg)

  • First-in-Class Dual GIP/GLP-1 Receptor Agonist: 39aa twincretin with imbalanced dual agonism favoring GIPR, biased GLP-1R signaling (cAMP > beta-arrestin), FDA-approved Mounjaro (T2D 2022)/Zepbound (obesity 2023), 3,000+ publications
  • Unprecedented Weight Loss Efficacy: SURMOUNT-1 (Jastreboff et al., 2022, NEJM): 22.5% mean body weight reduction at 72 weeks, 39.7% participants achieved ≥25% loss, SURMOUNT-5 superior to semaglutide
  • Clinical Status: SURPASS-CVOT cardiovascular non-inferiority vs dulaglutide with 16% lower all-cause mortality (HR 0.84), SUMMIT trial 38% reduction CV death/worsening HF in HFpEF+obesity (HR 0.62), SYNERGY-NASH 73.3% MASH resolution at 15mg
  • Mechanistic pathway studies
  • In vitro receptor profiling
  • HPLC verified identity and purity
$129.00In Stock

Ships same-day if ordered before 2PM EST

1
Encrypted Checkout
Global Express

Research Overview

T-GLP-1 (Tirzepatide) 15mg – Dual Incretin Receptor Agonist Research Peptide Tirzepatide is a novel 39-amino acid linear chimeric peptide designed for in vitro metabolic research. As an imbalanced dual agonist, it demonstrates equal affinity for GIPR compared to native GIP while exhibiting approximately 5-fold weaker affinity for GLP-1R than native GLP-1. Research Applications: This dual receptor agonist enables investigation of: - Incretin Receptor Signaling Pathways: Studies of Gαs/cAMP second messenger activation, biased agonism at GLP-1R favoring cAMP generation over β-arrestin recruitment, and differential receptor desensitization mechanisms - Glucose Homeostasis and Insulin Secretion: Pancreatic islet cell assays examining insulinotropic effects, β-arrestin1-mediated insulin response modulation, and synergistic GIP/GLP-1 co-activation effects - Adipocyte Metabolism and Lipid Regulation: GIPR-mediated adipose tissue function, AMPK and PPAR pathway activation, lipid oxidation mechanisms - Receptor Binding and Structural Biology: Cryo-EM structural analysis of receptor-ligand complexes, investigation of Tyr1 positioning and fatty acid modification tolerance - Metabolic Disease Models: Diet-induced obesity models, insulin resistance assays, glucose tolerance testing Molecular Mechanism: Structural studies reveal tirzepatide's GIP-based sequence with C20 lysine-linked fatty diacid modification and two α-aminoisobutyric acid (Aib) residues. The C-terminal amidation facilitates albumin binding and extended half-life. At GLP-1R, high-affinity extracellular domain binding coupled with Tyr1-induced decreased stability produces biased signaling and reduced internalization. Product Specifications: - Chemical Formula: C225H348N48O68 - Molecular Weight: 4813.5 g/mol - Purity: ≥98% (HPLC verified) - Form: Lyophilized powder - Storage: -20°C, protected from light and moisture - Supplied with: Certificate of Analysis Laboratory Use Only: This product is manufactured exclusively for scientific research and laboratory applications by qualified researchers in controlled settings. It is NOT intended for human consumption, veterinary use, or diagnostic purposes. Handling Requirements: Store lyophilized peptide at -20°C in original sealed vial. Minimize freeze-thaw cycles; prepare single-use aliquots after reconstitution. Reconstituted solutions stable for 48 hours at 4°C or 30 days at -20°C. Regulatory Compliance: This material is provided for research purposes only. Purchaser assumes full responsibility for compliance with applicable local, state, and federal regulations. Certificate of Analysis (CoA) available upon request.

This product is intended exclusively for in vitro laboratory research by qualified professionals. Not for human consumption. Not approved by the FDA.

Published Research Briefs

Our research team has published evidence-checked briefs covering the science behind this compound. Each brief reviews primary sources and grades claims independently.